NCT01430091View on ClinicalTrials.gov

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Sickle Cell Disease
Interventions
DRUG

Prasugrel (clinical formulation)

Administered orally

DRUG

Prasugrel (Orally Disintegrating Tablet [ODT])

Administered orally

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01430091 - A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet | Biotech Hunter | Biotech Hunter